Robert Vranian
Cardiovascular Disease · Fredericksburg, VANPI 1083601611
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,134 of the $13,951 with a category attached, or 87.0%. Amgen accounts for 89.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $9,780 and has fallen 98.4% since, to $161 in 2021. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $160.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$12K
- AstraZeneca$220
- Astellas Pharma US Inc$195
- Pfizer$177
- Akcea Therapeutics, Inc.$126
- Novartis$104
- plus $634 from 20 others
Across 1 payment — averaging $1668.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$2K
What the payments were for
- Speaking & faculty fees$12,13487%
- Food & beverage$1,70612%
- Education$1001%
- Entertainment$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $12,495 |
| AstraZeneca | 13 | $220 |
| Astellas Pharma US Inc | 6 | $195 |
| Pfizer | 6 | $177 |
| Akcea Therapeutics, Inc. | 1 | $126 |
| Novartis | 7 | $104 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| Portola Pharmaceuticals, LLC | 2 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $58 |
| Johnson & Johnson | 4 | $56 |
| Nuwellis, Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $50 |
| United Therapeutics Corporation | 2 | $44 |
| AbbVie | 2 | $28 |
| Abbott | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Bayer | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Medtronic | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Itamar Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,951 in reported general payments places this provider in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Fredericksburg
- Ramakota ReddyFredericksburg$16K
- Harish ChandraFredericksburg$13K
- Ashok PrasadFredericksburg$12K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.